UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

RP 64477: A potent inhibitor of acyl-coenzyme A: Cholesterol O-acyltransferase with low systemic bioavailability

Biochemical pharmacology, 1996-02, Vol.51 (4), p.413-421

1996

Volltextzugriff (PDF)

RP 64477: A potent inhibitor of acyl-coenzyme A

Biochemical pharmacology, 1996-02, Vol.51 (4), p.413-421

1996

Volltextzugriff (PDF)

Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer

Clinical cancer research, 2017-09, Vol.23 (18), p.5394-5405

2017

Volltextzugriff (PDF)

Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time‐Varying Clearance

Clinical pharmacology and therapeutics, 2019-11, Vol.106 (5), p.1018-1027

2019

Volltextzugriff (PDF)

Downregulation of inflammatory erectile dysfunction by Mantisa religiosa egg-cake through NO-cGMP-PKG dependent NF-kB signaling cascade activated by mixture of salt intake

Toxicology reports, 2023-01, Vol.10, p.633-646

2023

Volltextzugriff (PDF)

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

Journal of clinical oncology, 2012-04, Vol.30 (12), p.1371-1377

2012

Volltextzugriff (PDF)

Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors

Journal of clinical pharmacology, 2017-10, Vol.57 (S10), p.S26-S42

2017

Volltextzugriff (PDF)

Model‐Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors

Clinical pharmacology and therapeutics, 2024-03, Vol.115 (3), p.488-497

2024

Volltextzugriff (PDF)

Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment

Clinical pharmacokinetics, 2022-10, Vol.61 (10), p.1405-1416

2022

Volltextzugriff (PDF)

Model‐based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer

British journal of clinical pharmacology, 2024-07, Vol.90 (11), p.2920-2930

2024

Volltextzugriff (PDF)

Model‐Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non–Small Cell Lung Cancer

Journal of clinical pharmacology, 2019-10, Vol.59 (10), p.1415-1424

2019

Volltextzugriff (PDF)

Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants

Clinical pharmacokinetics, 2022-06, Vol.61 (6), p.857-867

2022

Volltextzugriff (PDF)

Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors

Clinical cancer research, 2024-07, Vol.30 (14), p.3050-3058

2024

Volltextzugriff (PDF)

Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs

Journal of clinical oncology, 2024-09

2024

Volltextzugriff (PDF)

Polymeric Nanoparticles for Increased Oral Bioavailability and Rapid Absorption Using Celecoxib as a Model of a Low-Solubility, High-Permeability Drug

Pharmaceutical research, 2012-02, Vol.29 (2), p.427-440

2012

Volltextzugriff (PDF)

Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2017-05, Vol.389 (10084), p.2105-2116

2017

Volltextzugriff (PDF)

Abstract 4120: Dose selection and dosing optimization of immune checkpoint inhibitors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4120-4120

2019

Volltextzugriff (PDF)

Linking Tumor Growth Dynamics to Survival in Ipilimumab‐Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling

CPT: pharmacometrics and systems pharmacology, 2019-11, Vol.8 (11), p.825-834

2019

Volltextzugriff (PDF)

Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma

Clinical cancer research, 2022-04, Vol.28 (8), p.1603-1613

2022

Volltextzugriff (PDF)

SINGLE-DOSE PHARMACOKINETICS OF BMS-986177/JNJ-70033093 (BMS-177/JNJ-3093) IN PARTICIPANTS WITH NORMAL RENAL FUNCTION AND PARTICIPANTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT

Journal of the American College of Cardiology, 2021-05, Vol.77 (18), p.1839-1839

2021

Volltextzugriff (PDF)

The growth performance and nutrient digestibility of pigs fed rain tree (Albizia saman) pods as a replacement for maize

Journal of agricultural sciences (Belgrade, Serbia), 2022, Vol.67 (3), p.285-298

2022

Volltextzugriff (PDF)

Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers

Cancer chemotherapy and pharmacology, 2019-04, Vol.83 (4), p.705-715

2019

Volltextzugriff (PDF)

Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects

Journal of clinical pharmacology, 2015-01, Vol.55 (1), p.104-113

2015

Volltextzugriff (PDF)

The Nigeria Parkinson Disease Registry: Process, Profile, and Prospects of a Collaborative Project

Movement disorders, 2020-08, Vol.35 (8), p.1315-1322

2020

Volltextzugriff (PDF)

Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma

Journal of pharmacokinetics and pharmacodynamics, 2016-06, Vol.43 (3), p.243-257

2016

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(82)
Dissertationen
(1)

Sprache

Englisch
(83)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

RP 64477: A potent inhibitor of acyl-coenzyme A: Cholesterol O-acyltransferase with low systemic bioavailability

RP 64477: A potent inhibitor of acyl-coenzyme A

Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer

Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time‐Varying Clearance

Downregulation of inflammatory erectile dysfunction by Mantisa religiosa egg-cake through NO-cGMP-PKG dependent NF-kB signaling cascade activated by mixture of salt intake

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors

Model‐Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors

Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment

Model‐based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer

Model‐Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non–Small Cell Lung Cancer

Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants

Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors

Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs

Polymeric Nanoparticles for Increased Oral Bioavailability and Rapid Absorption Using Celecoxib as a Model of a Low-Solubility, High-Permeability Drug

Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial

Abstract 4120: Dose selection and dosing optimization of immune checkpoint inhibitors

Linking Tumor Growth Dynamics to Survival in Ipilimumab‐Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling

Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma

SINGLE-DOSE PHARMACOKINETICS OF BMS-986177/JNJ-70033093 (BMS-177/JNJ-3093) IN PARTICIPANTS WITH NORMAL RENAL FUNCTION AND PARTICIPANTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT

The growth performance and nutrient digestibility of pigs fed rain tree (Albizia saman) pods as a replacement for maize

Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers

Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects

The Nigeria Parkinson Disease Registry: Process, Profile, and Prospects of a Collaborative Project

Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma

Suchergebnisse filtern